Connect Biopharma Holdings Inc (CNTB)

Form 4 - Statement of changes in beneficial ownership of securities

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report...

Form EFFECT - Notice of Effectiveness

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form F-3 - Registration statement by foreign private issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on...

Form 8-K - Current report

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report